Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says

Executive Summary

Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System

You may also be interested in...



Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb

The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested

Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb

The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested

AstraZeneca Expands Pipeline With “Reduced Risk” Phase III Program

AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories

Related Content

UsernamePublicRestriction

Register

PS046802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel